These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 10391881)

  • 1. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
    J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
    J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
    Cole NB; Murphy DD; Grider T; Rueter S; Brasaemle D; Nussbaum RL
    J Biol Chem; 2002 Feb; 277(8):6344-52. PubMed ID: 11744721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Spillantini MG; Goedert M
    Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
    Iwatsubo T
    J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
    Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
    Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
    Biere AL; Wood SJ; Wypych J; Steavenson S; Jiang Y; Anafi D; Jacobsen FW; Jarosinski MA; Wu GM; Louis JC; Martin F; Narhi LO; Citron M
    J Biol Chem; 2000 Nov; 275(44):34574-9. PubMed ID: 10942772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
    El-Agnaf OM; Jakes R; Curran MD; Wallace A
    FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
    Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
    J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
    Bickle L; Hopwood JJ; Karageorgos L
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease.
    Mezey E; Dehejia AM; Harta G; Tresser N; Suchy SF; Nussbaum RL; Brownstein MJ; Polymeropoulos MH
    Mol Psychiatry; 1998 Nov; 3(6):493-9. PubMed ID: 9857974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
    Iwatsubo T
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
    Kang JH; Kim KS
    Mol Cells; 2003 Feb; 15(1):87-93. PubMed ID: 12661766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
    Braak H; Sandmann-Keil D; Gai W; Braak E
    Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases.
    El-Agnaf OM; Curran MD; Wallace A; Middleton D; Murgatroyd C; Curtis A; Perry R; Jaros E
    Neuroreport; 1998 Dec; 9(17):3925-7. PubMed ID: 9875730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.